0722 (0722) Fair Value & Analysis

Healthcare · Market cap HK$369M

0 0722 0722 · HK

PriceHK$0.4550

Fair ValueHK$0.8500

Upside+86.8%

Quality67/100

Evidence: High Range HK$0.6400 – HK$1.07

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −4.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3638 – HK$0.4950 · fair‑value band HK$0.6400 – HK$1.07 · the HK$0.4550 price screens below the HK$0.8500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0722 (0722) currently trades at HK$0.4550, while our model-based Fair Value estimate is HK$0.8500 — implying the stock looks roughly 86.8% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0722 generated revenue of HK$724M at a net margin of 4.4%. Revenue declined 1.0% year over year. It earns a return on equity of 4.4%. The balance sheet holds a net cash position of HK$141M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$724M

Revenue growth (YoY) -1.0%

Net margin 4.4%

Return on equity 4.4%

Free cash flow HK$134M FY2025

P/E ratio 11.4

More key figures

Operating margin 6.3%

EPS (TTM) HK$0.0400

Dividend yield 7.1%

EPS growth (YoY) +5.1%

Net cash HK$141M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0722 reported revenue of HK$727M in FY2025 versus HK$617M in FY2021, a compound +4.2%/yr. Reported net income was HK$31.4M in FY2025, compounding −2.5%/yr from FY2021.

Revenue +4.2%/yr

FY21 HK$617M

FY22 HK$666M

FY23 HK$728M

FY24 HK$748M

FY25 HK$727M

Net income −2.5%/yr

FY21 HK$34.8M

FY22 HK$72.2M

FY23 HK$60.5M

FY24 HK$40.6M

FY25 HK$31.4M

Is 0722 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0722 (0722) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8500 versus a price of HK$0.4550 — about +87% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0722?

Our model-based fair value for 0722 is HK$0.8500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4550.

What is the quality score of 0722?

0722 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0722 (0722)?

0722 reported trailing-twelve-month revenue of about HK$724M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0722?

The net profit margin of 0722 is about 4.4%, meaning it keeps roughly 4.4% of revenue as net income. Based on the latest reported figures.

Does 0722 pay a dividend?

0722 currently shows a dividend yield of about 7.10% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.